156 related articles for article (PubMed ID: 32816233)
1. Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D; Kim J; Yun J; Park SJ
Adv Ther; 2020 Oct; 37(10):4308-4324. PubMed ID: 32816233
[TBL] [Abstract][Full Text] [Related]
2. Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties.
Yun J; Kim J; Chung J; Hwang SJ; Park SJ
Adv Ther; 2019 Jul; 36(7):1700-1714. PubMed ID: 31102205
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical and Biological Stability Assessment of SB11 (Ranibizumab Biosimilar) Under Ambient and In-Use Storage for Intravitreal Administration.
Kaiser PK; Yun J; Kim S; Kim J; Park SJ
Ophthalmol Ther; 2023 Apr; 12(2):985-998. PubMed ID: 36607595
[TBL] [Abstract][Full Text] [Related]
4. In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Tak M; Jeong H; Yun J; Kim J; Kim S; Lee Y; Park SJ
Drugs R D; 2023 Dec; 23(4):363-375. PubMed ID: 37606749
[TBL] [Abstract][Full Text] [Related]
5. Prolonged In-use Stability of Diluted Atezolizumab in Commercial Intravenous Bags.
Hui A; Yin J; Liu W; Zheng K
Int J Pharm Compd; 2021; 25(3):246-257. PubMed ID: 34125716
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev
Weiser S; Burns C; Zartler ER
J Oncol Pharm Pract; 2023 Jul; 29(5):1032-1043. PubMed ID: 35312402
[TBL] [Abstract][Full Text] [Related]
7. Thermal stability and storage of human insulin.
Richter B; Bongaerts B; Metzendorf MI
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015385. PubMed ID: 37930742
[TBL] [Abstract][Full Text] [Related]
8. Short-term study on in-use stability of opened bevacizumab biosimilar PF-06439535 vials.
Abdel-Tawab M; Waßmuth M; Gegenfurtner F; Hawe A; Schefe JH; Strunz AM; Wübert J
Eur J Hosp Pharm; 2022 Jul; 31(2):135-42. PubMed ID: 35853692
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of physicochemical and biological properties of nonreconstituted MYL-1401O vials, reconstituted MYL-1401O suspension in vial, and diluted MYL-1401O suspension in infusion bags (0.9% saline) for extended duration.
Vats B; Goyal P; Mathew Z; Ghosh R; Babu MN; Jadav RS; Nair AM; Subbarao M; Bera A; Prakash Sadasivappa K; Kabadi P; Sarkar A; Honnappa CG; Patnaik US; Singh A; Parambath AV; Ullanat R
Expert Opin Biol Ther; 2022 Feb; 22(2):299-311. PubMed ID: 33896318
[TBL] [Abstract][Full Text] [Related]
10. Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion.
Vimpolsek M; Gottar-Guillier M; Rossy E
Drugs R D; 2019 Jun; 19(2):127-140. PubMed ID: 30810925
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion.
Guyader GL; Vieillard V; Paul M
J Oncol Pharm Pract; 2021 Jun; 27(4):847-856. PubMed ID: 32660375
[TBL] [Abstract][Full Text] [Related]
12. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
13. Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bags.
Vieillard V; Paul M; Ibrahim T; Astier A
Ann Pharm Fr; 2017 Nov; 75(6):420-435. PubMed ID: 28784243
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months.
Chen YH; Wu PC; Shiea J; Lo LH; Wu YC; Kuo HK
J Ocul Pharmacol Ther; 2009 Feb; 25(1):65-9. PubMed ID: 19232008
[TBL] [Abstract][Full Text] [Related]
15. SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation.
Peeters M; Lipp HP; Park M; Yoon YC; Arnold D
Future Oncol; 2023 Feb; 19(6):427-450. PubMed ID: 36883661
[TBL] [Abstract][Full Text] [Related]
16. Stability of 1-unit/mL insulin aspart solution in cyclic olefin copolymer vials and polypropylene syringes.
Henry H; Gilliot S; Genay S; Barthélémy C; Décaudin B; Odou P
Am J Health Syst Pharm; 2022 Apr; 79(8):665-675. PubMed ID: 34971359
[TBL] [Abstract][Full Text] [Related]
17. Extended physicochemical stability of cetuximab in opened vials and infusion bags when stored at 4°C and 25°C.
Vieillard V; Le Guyader G; Jallades A; Astier A
J Oncol Pharm Pract; 2024 Jan; 30(1):142-150. PubMed ID: 37078110
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera
Weiser S; Burns C; Zartler ER
J Oncol Pharm Pract; 2023 Apr; 29(3):590-600. PubMed ID: 35072574
[TBL] [Abstract][Full Text] [Related]
19. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Oct; 175():112742. PubMed ID: 31344647
[TBL] [Abstract][Full Text] [Related]
20. SB8: A Bevacizumab Biosimilar.
Syed YY
Target Oncol; 2020 Dec; 15(6):787-790. PubMed ID: 33206282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
